Abstract
From previous fits of drug transport kinetics across confluent Madin-Darby canine kidney II cell line overexpressing human multidrug resistance 1 cell monolayers, we found that a drug's binding constant to P-glycoprotein (P-gp) was significantly smaller than its IC50 when that drug was used as an inhibitor against another P-gp substrate. We tested several IC50 candidate functions, including the standard function, the Kalvass-Pollack function, and the efflux ratio, to determine whether any of them yielded an IC50 = KI, as would be expected for water-soluble enzymes. For the confluent cell monolayer, the IC50/KI ratio is greater than 1 for all candidate functions tested. From the mass action kinetic model, we have derived a simple approximate equation that shows how the IC50/KI ratio depends on the elementary rate constants from our mass action model. Thus, the IC50 will differ between cell lines and tissues, for the same probe substrate and inhibitor, if there are different membrane concentrations of P-gp, or the probe substrate's elementary rate constants, partition coefficient, binding constant to P-gp, passive permeability, and ability to access the other transporters (if any) in the two cell lines. The mass action model and the approximate equation for the IC50/KI ratio derived here can be used to estimate the elementary rate constants needed to extrapolate in vitro drug-drug interactions for compounds to the in vivo environment.
Footnotes
-
↵ The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
doi:10.1124/dmd.109.029843.
-
- KI
- KD of a P-gp substrate when it is used as an inhibitor
- MDCKII-hMDR1
- Madin-Darby canine kidney II cell line overexpressing human multidrug resistance 1
- KC
- the substrate binding constant to P-gp relative to the lipid bilayer
- P-gp
- the P-glycoprotein product of the hMDR1 gene
- MRP
- multidrug resistance-associated protein
- GF120918
- N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide
- A>B (or B>A)
- transport across the confluent cell monolayer when the donor chamber is apical (or basolateral) and the receiver chamber is basolateral (or apical), respectively
- KD = 1/(KC∗KPC)
- substrate dissociation constant from P-gp relative to the aqueous concentration in the cytosol, where KPC is the substrate’
- Received August 20, 2009.
- Accepted November 2, 2009.
- Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|